Cris Loiren Rodriguez

Array ( [id] => 13400001 [patent_doc_number] => 20180251543 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2018-09-06 [patent_title] => POLYNUCLEOTIDES ENCODING MONOCLONAL ANTIBODIES THAT BIND BOTH IL-17A AND IL-17F [patent_app_type] => utility [patent_app_number] => 15/980325 [patent_app_country] => US [patent_app_date] => 2018-05-15 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 37130 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -3 [patent_words_short_claim] => 69 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 15980325 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 15512783 [patent_doc_number] => 10562967 [patent_country] => US [patent_kind] => B2 [patent_issue_date] => 2020-02-18 [patent_title] => Treating inflammation with IL-17/IL-23 bispecific antibodies [patent_app_type] => utility [patent_app_number] => 15/974183 [patent_app_country] => US [patent_app_date] => 2018-05-08 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 45458 [patent_no_of_claims] => 4 [patent_no_of_ind_claims] => 2 [patent_words_short_claim] => 102 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 15974183 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 13590025 [patent_doc_number] => 20180346561 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2018-12-06 [patent_title] => ANTIBODY MOLECULES WHICH BIND IL-17A AND IL-17F [patent_app_type] => utility [patent_app_number] => 15/974407 [patent_app_country] => US [patent_app_date] => 2018-05-08 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 10715 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -19 [patent_words_short_claim] => 2 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 15974407 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 15556811 [patent_doc_number] => 20200062817 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2020-02-27 [patent_title] => CRETION-COMPETENT MUTEINS OF THE HUMAN IL-27 ALPHA-SUBUNIT [patent_app_type] => utility [patent_app_number] => 16/609726 [patent_app_country] => US [patent_app_date] => 2018-05-04 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 23302 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -17 [patent_words_short_claim] => 2 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16609726 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 14132387 [patent_doc_number] => 20190100583 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2019-04-04 [patent_title] => IL-17A/F HETEROLOGOUS POLYPEPTIDES AND THERAPEUTIC USES THEREOF [patent_app_type] => utility [patent_app_number] => 15/965115 [patent_app_country] => US [patent_app_date] => 2018-04-27 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 61358 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -19 [patent_words_short_claim] => 2 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 15965115 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 16506216 [patent_doc_number] => 20200385472 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2020-12-10 [patent_title] => MULTISPECIFIC MOLECULES COMPRISING A NON-IMMUNOGLOBULIN HETERODIMERIZATION DOMAIN AND USES THEREOF [patent_app_type] => utility [patent_app_number] => 16/607154 [patent_app_country] => US [patent_app_date] => 2018-04-27 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 45875 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -106 [patent_words_short_claim] => 31 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16607154 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 13536673 [patent_doc_number] => 20180319880 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2018-11-08 [patent_title] => ANTI-CGRP/ANTI-IL-23 BISPECIFIC ANTIBODIES AND USES THEREOF [patent_app_type] => utility [patent_app_number] => 15/963167 [patent_app_country] => US [patent_app_date] => 2018-04-26 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 14595 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -17 [patent_words_short_claim] => 100 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 15963167 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 15496301 [patent_doc_number] => 20200048339 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2020-02-13 [patent_title] => USE OF IL-20 ANTAGONISTS FOR TREATING EYE DISEASES [patent_app_type] => utility [patent_app_number] => 16/607686 [patent_app_country] => US [patent_app_date] => 2018-04-25 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 17411 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -20 [patent_words_short_claim] => 37 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16607686 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 20645822 [patent_doc_number] => 12600757 [patent_country] => US [patent_kind] => B2 [patent_issue_date] => 2026-04-14 [patent_title] => Peptides inhibiting gamma-c-cytokine activity and methods of use [patent_app_type] => utility [patent_app_number] => 16/603040 [patent_app_country] => US [patent_app_date] => 2018-04-04 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 18 [patent_figures_cnt] => 18 [patent_no_of_words] => 27000 [patent_no_of_claims] => 16 [patent_no_of_ind_claims] => 2 [patent_words_short_claim] => 43 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16603040 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 19504986 [patent_doc_number] => 12116397 [patent_country] => US [patent_kind] => B2 [patent_issue_date] => 2024-10-15 [patent_title] => IL-IR-I binding polypeptide [patent_app_type] => utility [patent_app_number] => 16/498186 [patent_app_country] => US [patent_app_date] => 2018-04-03 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 65 [patent_figures_cnt] => 65 [patent_no_of_words] => 36601 [patent_no_of_claims] => 25 [patent_no_of_ind_claims] => 2 [patent_words_short_claim] => 34 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16498186 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 13314253 [patent_doc_number] => 20180208663 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2018-07-26 [patent_title] => IL2RBETA/COMMON GAMMA CHAIN ANTIBODIES [patent_app_type] => utility [patent_app_number] => 15/922921 [patent_app_country] => US [patent_app_date] => 2018-03-16 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 23138 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -12 [patent_words_short_claim] => 177 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 15922921 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 13987357 [patent_doc_number] => 20190062836 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2019-02-28 [patent_title] => METHODS OF PROGNOSING, DIAGNOSING AND TREATING IDIOPATHIC PULMONARY FIBROSIS [patent_app_type] => utility [patent_app_number] => 15/924114 [patent_app_country] => US [patent_app_date] => 2018-03-16 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 32923 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -27 [patent_words_short_claim] => 2 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 15924114 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 15102245 [patent_doc_number] => 10472423 [patent_country] => US [patent_kind] => B2 [patent_issue_date] => 2019-11-12 [patent_title] => IL2Rbeta/common gamma chain antibodies [patent_app_type] => utility [patent_app_number] => 15/908218 [patent_app_country] => US [patent_app_date] => 2018-02-28 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 67 [patent_figures_cnt] => 68 [patent_no_of_words] => 23146 [patent_no_of_claims] => 5 [patent_no_of_ind_claims] => 1 [patent_words_short_claim] => 50 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 15908218 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 13399959 [patent_doc_number] => 20180251522 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2018-09-06 [patent_title] => IL-22BP COMPOSITIONS AND METHOD FOR THE TREATMENT OF DISEASE THEREWITH [patent_app_type] => utility [patent_app_number] => 15/901512 [patent_app_country] => US [patent_app_date] => 2018-02-21 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 11178 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -16 [patent_words_short_claim] => 2 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 15901512 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 12885157 [patent_doc_number] => 20180186894 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2018-07-05 [patent_title] => TARGETED MODIFIED IL-1 FAMILY MEMBERS [patent_app_type] => utility [patent_app_number] => 15/901545 [patent_app_country] => US [patent_app_date] => 2018-02-21 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 6970 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -9 [patent_words_short_claim] => 18 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 15901545 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 13413245 [patent_doc_number] => 20180258165 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2018-09-13 [patent_title] => ANTIBODIES AGAINST IL-1 BETA [patent_app_type] => utility [patent_app_number] => 15/896309 [patent_app_country] => US [patent_app_date] => 2018-02-14 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 12809 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -55 [patent_words_short_claim] => 45 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 15896309 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 13342893 [patent_doc_number] => 20180222986 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2018-08-09 [patent_title] => CANCER METASTASIS INHIBITOR [patent_app_type] => utility [patent_app_number] => 15/877894 [patent_app_country] => US [patent_app_date] => 2018-01-23 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 15204 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -6 [patent_words_short_claim] => 2 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 15877894 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 16012787 [patent_doc_number] => 20200181236 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2020-06-11 [patent_title] => BISPECIFIC FUSION PROTEIN FOR IL-17 AND TNF-alpha [patent_app_type] => utility [patent_app_number] => 16/637246 [patent_app_country] => US [patent_app_date] => 2018-01-18 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 3750 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -19 [patent_words_short_claim] => 196 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16637246 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 13300229 [patent_doc_number] => 20180201651 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2018-07-19 [patent_title] => PHARMACEUTICAL COMPOSITION THAT IS ANTICANCER AND SUPPRESSES CANCER METASTASIS, CONTAINING, AS ACTIVE INGREDIENT, FUSION PEPTIDE SIMULTANEOUSLY TARGETING CANCER CELL AND TUMOR ASSOCIATED MACROPHAGE [patent_app_type] => utility [patent_app_number] => 15/856740 [patent_app_country] => US [patent_app_date] => 2017-12-28 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 9080 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -7 [patent_words_short_claim] => 40 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 15856740 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 13297603 [patent_doc_number] => 20180200338 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2018-07-19 [patent_title] => COMBINATION THERAPY OF TUMOR-TARGETED IL-2 VARIANT IMMUNOCYTOKINES AND ANTIBODIES AGAINST HUMAN PD-L1 [patent_app_type] => utility [patent_app_number] => 15/851253 [patent_app_country] => US [patent_app_date] => 2017-12-21 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 43584 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -11 [patent_words_short_claim] => 511 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 15851253 [rel_patent_id] =>[rel_patent_doc_number] =>)